Assessing Evidence Readiness

#Match evidence to the decision

Evidence readiness is not a single label that applies to every use of a tool or process. The central question is whether the available evidence supports the next proposed activity. Evidence sufficient for an exploratory study may be inadequate for a change that directly influences routine clinical decisions.

Describe the intended users, population, setting and role of the approach. Ask whether it provides background information, recommends an action or performs a task with limited oversight. The consequences of failure and the ability to detect or reverse errors affect how much assurance is needed before proceeding.

#Look beyond a headline result

Review how evidence was produced. Relevant questions include how participants or records were selected, what comparison was used, whether outcomes were meaningful and how missing information was handled. Small or narrowly selected samples can leave substantial uncertainty even when reported results appear favourable. Estimates should be considered alongside their uncertainty.

Distinguish technical performance from clinical benefit and operational usefulness. A system may perform well on stored data without improving decisions in practice. Check whether evaluation involved the intended users and conditions, whether findings have been examined independently and whether harms or differences between groups were assessed.

#Record gaps and proportionate next steps

Create a short evidence table linking each important claim to its supporting findings, limitations and relevance. Identify unanswered questions about safety, effectiveness, usability and performance over time. An absence of reported harm is not proof of safety, particularly when an evaluation was not designed to detect uncommon problems.

Choose the next step according to the gaps and potential consequences. Options may include further analysis, task-based testing, a carefully governed evaluation or not proceeding. Define what new evidence would change the decision. Readiness should be reassessed when the intended use, population, system or care process changes materially.

#Common misunderstandings

Evidence readiness is not a stamp of approval that applies to every situation. Findings may be adequate for a limited, closely monitored use but insufficient for a decision with serious or irreversible consequences. The intended use matters as much as the amount of research available.

More studies do not automatically mean stronger evidence. Several studies with similar weaknesses can leave the same important question unanswered. Equally, a promising result is not necessarily a meaningful benefit: a change in a test score or measurement may not translate into better health or daily functioning.

Uncertainty also does not mean that an approach has no value. It means the limits of current knowledge need to remain visible. Nor does an absence of reported harm establish safety, especially when studies are small or brief. Readiness is a reasoned judgment that can change as better findings emerge, not a permanent label.

#Questions worth asking a clinician

• What specific clinical use and decision was this evidence designed to support, and does that match the proposed use in my care?
• Do the studies show better health outcomes in real care, or only accurate predictions or measurements under test conditions?
• How well do the study participants and care settings match my circumstances, and which differences could make the findings less applicable?
• Given the consequences of a wrong decision, is the available evidence strong enough to justify this use?
• What important uncertainties remain, and what additional studies or results would be needed before using this approach in my care?